In addition, CDCA8 silencing sensitizes ovarian cancer cells to olaparib and cisplatin via induction of the G2/M phase arrest, acceleration of cell apoptosis, enhancement of DNA damage, and interference with RAD51 accumulation in vitro.12 Here, RAD51 is linked to ovarian carcinoma.